The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Development of daptomycin for Gram-positive infections
Abstract
Gram-positive bacteria are an important cause of serious infections, particularly those originating in hospitals, and are becoming increasingly resistant to many antibiotics hitherto regarded as standard therapy for these infections.1 Daptomycin is an investigational antibiotic that kills most clinically significant Gram-positive bacteria.2–4 These include resistant pathogens for which there are very few therapeutic alternatives, such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide intermediately susceptible S. aureus (GISA), coagulase-negative staphylococci (CNS) and penicillin-resistant Streptococcus pneumoniae (PRSP). The cyclic lipopeptide daptomycin (Figure 1) is a fermentation product of Streptomyces roseosporus. It was discovered in the early 1980s, at Eli Lilly and Company (Lilly), and was developed as LY 146032 for intravenous treatment of serious Gram-positive infections. Nineteen Phase 1 and two Phase 2 clinical studies involving more than 370 subjects were conducted in the 1980s and early 1990s. The results in skin and soft tissue infections and bacteraemia were encouraging, and clinical results with endocarditis suggested the potential for efficacy at higher doses.3,4 However, Lilly was not satisfied with the overall clinical results observed with the twice-daily dosing regimen utilized in these studies. In 1997, Cubist Pharmaceuticals Inc. (Cubist) licensed worldwide rights from Lilly with the intention of developing daptomycin for the treatment of serious Gram-positive infections in hospitalized patients. Clinical trials conducted by Cubist commenced in the USA and Europe in 1999. Daptomycin has a unique mechanism of action, killing Gram-positive bacteria by disrupting multiple aspects of bacterial plasma membrane function without penetrating into the cytoplasm.5–7 The drug exhibits rapid, concentration-dependent bactericidal activity in vitro against Gram-positive organisms, including enterococci (Figure 2).8–13 It acts against most clinically significant Gram-positive bacteria but not against Gram-negative bacteria. Daptomycin's antibacterial activity against antibiotic-resistant strains such as MRSA, VRE and PRSP is comparable to that against antibiotic-susceptible strains of these species. The MIC of daptomycin for antibiotic-susceptible strains is typically four-fold lower than that of vancomycin. Daptomycin produces a post-antibiotic effect (PAE) and regrowth times in vitro that are prolonged and concentration dependent.8,14 PAEs lasting from 1 to 6 h were observed against Enterococcus faecalis and S. aureus after exposure to daptomycin concentrations ranging from 0.25 to 16 mg/L (from one- to eight-fold the MIC). Spontaneous acquisition of resistance to daptomycin is rare.15,16 Resistant organisms have been isolated by serial passage in liquid media containing incremental subinhibitory concentrations of daptomycin. Resistant isolates of S. aureus have also been isolated following chemical mutagenesis with N-methyl-N′-nitro-N-nitrosoguanidine.16 The results of in vitro interaction studies suggest that daptomycin will not adversely affect the activity of other antimicrobials. Against 70 clinical isolates, interactions with 25 antimicrobials were additive or indifferent; antagonism was not observed.4 Synergic interactions occurred between daptomycin and gentamicin against staphylococci and enterococci. Daptomycin has been shown to be effective in a number of in vivo animal models of bacterial infection of the soft tissues, bloodstream, kidneys, heart, lungs and bone, including those caused by Gram-positive strains resistant to standard therapies (e.g. MRSA and VRE).4,15,17–27 Pharmacodynamic studies in mice have suggested that daptomycin's bactericidal activity is concentration dependent.28–30 In laboratory animals, daptomycin has been associated with adverse effects that involve skeletal muscle, kidneys, the gastrointestinal tract and the nervous system.4 Skeletal muscle is the tissue most sensitive to the adverse effects of daptomycin. Mild myopathy was easily predicted and monitored by measuring serum creatine phosphokinase (CPK) concentrations and was reversible upon cessation of therapy. Axonal degeneration of peripheral nerves occurred at dose levels approximately four-fold higher than for myopathy. Renal and gastrointestinal toxicities were noted only in rats. Skeletal muscle adverse effects were dependent on dosing frequency as well as dose level. Dog studies showed that skeletal muscle adverse effects were greater with fractionated compared with once-daily administration of the same total daily dose.31 Thus, once-daily dosing may increase the therapeutic-toxicity ratio by increasing efficacy and decreasing skeletal muscle adverse effects, as demonstrated in pharmacokinetic/pharmacodynamic models. With once-daily administration, daptomycin exhibits linear pharmacokinetics and minimal accumulation with doses up to 6 mg/kg
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
Daptomycin disrupts membrane potential in growing Staphylococcus aureus
Alborn, W. E., Allen, N. E., & Preston, D. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2282 · Cited by 213
Daptomycin: a novel agent for Gram-positive infections
Tally, F. P., Zeckel, M., Wasilewski, M. M., Carini, C., Berman, C. L., Drusano, G. L., & Oleson JR, F. B. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.8.1223 · Cited by 205
Self-citationCanepari, P., Boaretti, M., Lleò, M. M., & Satta, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1220 · Cited by 166
Hanberger, H., Nilsson, L. E., Maller, R. K., et al. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1710 · Cited by 139
Effect of protein binding of daptomycin on MIC and antibacterial activity
Lee, B. L., Sachdeva, M., & Chambers, H. F. “. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.12.2505 · Cited by 133
Lamp, K. C., Rybak, M. J., Bailey, E. M., & Kaatz, G. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2709 · Cited by 131
Cantoni, L., Glauser, M. P., & Billé, J. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.12.2348 · Cited by 89
Kaatz, G. W., Seo, S. M., Reddy, V. N., et al. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.11.2081 · Cited by 61
Cited by
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Tackling antibiotic resistance
Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., Jacoby, G. A., Kishony, R., Kreiswirth, B. N., Kutter, E., et al. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2693 · Cited by 1,062
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Where will new antibiotics come from?
Walsh, C. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro727 · Cited by 755
Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design
Li, J., Koh, J.-J., Liu, S., Lakshminarayanan, R., Verma, C. S., & Beuerman, R. W. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00073 · Cited by 611
Straus, S. K., & Hancock, R. E. W. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.02.009 · Cited by 446
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Miao, V., Coëffet-LeGal, M.-F., Brian, P., Brost, R., Penn, J., Whiting, A., Martin, S., Ford, R., Parr, I., Bouchard, M., et al. (2005) · Microbiology · doi:10.1099/mic.0.27757-0 · Cited by 368
Carpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358
(2015) · Journal of Clinical and Translational Research · doi:10.18053/jctres.201503.002 · Cited by 340
The action mechanism of daptomycin
Taylor, S. D., & Palmer, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.052 · Cited by 298
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297
History of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Review of surfactin chemical properties and the potential biomedical applications
Seydlová, G., & Svobodová, J. (2008) · Open Medicine · doi:10.2478/s11536-008-0002-5 · Cited by 286
Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Drusano, G. L. (2010) · Clinical Infectious Diseases · doi:10.1086/652767 · Cited by 280
Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
Mave, V., Garcia-Diaz, J., Islam, T., & Hasbun, R. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp154 · Cited by 65
Grégoire, N., Marchand, S., Ferrandière, M., Lasocki, S., Seguin, P., Vourc’h, M., Barbaz, M., Gaillard, T., Launey, Y., Asehnoune, K., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky374 · Cited by 38
Metadata
- Authors
- Tally, F. P., & DeBruin, M. F.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-10-01
- Volume
- 46
- Issue
- 4
- Pages
- 523-526
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2137521215
- Cited by
- 321
- References
- 15
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.